Verdict — specimen
/v/nuclear
The reading
$10,000 into a basket of US-listed nuclear and uranium equities.
Equal weight, rebalanced yearly. Dividends reinvested.
2015–2026. Benchmark: S&P 500.
$0
$10,000 became $31,900 over 2015–2026. The same money in the S&P 500 became $34,600.
What you sat through
Worst stretch: −58.2%, January 2016 to November 2016 — you would have sat through ten months of that.
Counter-test
Same rule, idle cash in T-bills: $32,400.
Where the thesis was wrong
The thesis was right about the direction and wrong about the entry. Almost all of the gain arrived after 2023. For the eight years before it, this basket lost to the index in every calendar year but one.
What this verdict does not include
US-listed stocks and ETFs only. End-of-day prices. No tax, no trading fees, no slippage. Survivorship is not corrected for. The figures in this specimen are illustrative; run your own thesis and every number on the page is computed from stored closes.

